Ensuring timely antibody delivery in the face of supply chain challenges - contact us for solutions

Goat Anti-Human IgM, Mouse/Bovine/Horse SP ads-FITC

Cat. No.:
2023-02
Goat Anti-Human IgM-FITC antibody with minimal reactivity to mouse, bovine, and horse serum proteins for use in fluorescent assays.
$127.00
Size Price (USD) Quantity
1.0 mg $127.00
More Information
Isotype Goat IgG
Isotype Control Goat IgG-FITC
Specificity Reacts with the heavy chain of human IgM
Source Pooled antisera from goats hyperimmunized with human IgM
Cross Adsorption Human IgG and IgA; mouse, bovine, and horse serum proteins (SP); may react with IgM from other species
Purification Method Affinity chromatography on human IgM covalently linked to agarose
Conjugate FITC (Fluorescein)
Buffer Formulation Phosphate buffered saline containing < 0.1% sodium azide
Clonality Polyclonal
Concentration 1.0 mg/mL
Volume 1.0 mL
Recommended Storage 2-8°C; Avoid exposure to light
Applications Quality tested applications for relevant formats include -
ELISA 1-4
FLISA

RRID Number AB_2795620
Gene ID 3507 (Human)
Gene ID Symbol IGHM (Human)
Gene ID Aliases AGM1; MU; VH
UniProt ID P01871 (Human
UniProt Name IGHM_HUMAN (Human)

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view


Need help with this product?
or call 800.722.2255
  1. 1. Magnani DM, Rogers TF, Beutler N, Ricciardi MJ, Bailey VK, Gonzalez-Nieto L, et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci Transl Med. 2017;9:eaan8184. (ELISA)
  2. 2. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5:eabe5511. (ELISA)
  3. 3. Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, et al. with humoral immunodeficiency. Cell Rep Med. 2020;2:100164. (ELISA)
  4. 4. Zhang B, Huo J, Huang Y, Teo SY, Duan K, Li Y, et al. mRNA booster vaccination enhances antibody responses against SARS-CoV2 omicron variant in individuals primed with mRNA or inactivated virus vaccines. Vaccines (Basel). 2022;10:1057. (ELISA)
See All References